Videos

How Eyenovia Aims to Solve the Problem of Eyedroppers

By Mario Admin | May 17, 2016

The natural solution to the problems associated with delivering drops to the front of the eye is inkjet printing, Eyenovia director Curt LaBelle, MD, told…

Read More

Goggles Target Pressure Differentials in Glaucoma

By Mario Admin | May 17, 2016

The idea for Equinox, and the first non-surgical, non-drug treatment for glaucoma, came to John Berdahl, MD, while he and his wife were scuba diving.…

Read More

PowerVision Shows `True Accommodation’

By Mario Admin | May 17, 2016

PowerVision has developed a fluid-controlled accommodating intraocular lens (IOL), the FluidVision AIOL, as the first platform to provide “true accommodation” by mimicking the eye’s natural…

Read More

Glaukos Recounts IPO Roadshow

By Mario Admin | May 17, 2016

Glaukos completed its IPO on June 25, 2015, but the road getting there was a long one. Before going public, the company that was founded…

Read More

InnFocus’ Trenary Discusses New Funding, Timeline

By Mario Admin | May 17, 2016

To watch InnFocus’ OIS Companies to Watch Presentaion Click Here InnFocus CEO Russ Trenary participated in our Glaucoma section of OIS@ASCRS. We caught up with…

Read More

Lindstrom Eyes Improvements to Eye Drops

By Mario Admin | May 16, 2016

Richard Lindstrom, MD, led the OIS@ASRCS breakfast breakout session “Innovative Alternatives to Drops.” Hear his recap of the problem and the potential solutions that may…

Read More

Masters of The Universe

By Mario Admin | May 13, 2016

The day concluded with the Masters of the Universe panel where AcuFocus executive chairman Jim Mazzo led a discussion between Link and executives from Abbott…

Read More
The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs - OIS@ASCRS 2016

The “Post-Game Wrap-Up” with OIS@ASCRS Co-Chairs

By Tom Salemi | May 13, 2016

OIS co-chairs and VCs Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, sit down with OISTV to review the highlights of the May…

Read More
Aerie’s CEO Says FDA, Investors Helped Get Company Back on Track

Aerie’s CEO Says FDA, Investors Helped Get Company Back on Track

By Tom Salemi | February 3, 2016

Aerie Pharmaceuticals Inc. didn’t quite enjoy the “roller coaster ride” that followed the disap-pointing results of Rocket 1, a trial testing Rhopressa, a potential treatment…

Read More

LacriPen Writing Exciting Script for Founders

By Tom Salemi | December 1, 2015

Interview

Read More

Opthea Taking New Approach to Combat Wet AMD

By Mario Admin | December 1, 2015

Megan Baldwin, PhD, Managing Director and CEO of Opthea, gives an update on OPT-302, a soluble receptor consisting of the first three extracellular domains of…

Read More

Ocular Therapeutix Taking Aim at Allergy Market

By Tom Salemi | November 30, 2015

Amar Sawhney, PhD, Chairman, Chairman, President & CEO of Ocular Therapeutics, touts the performance of Dextenza, the company’s anti-allergy medication. Instead of taking one drop…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.